Role of natural products in cardiovascular disease

Qi Dong1, Gaoying Dai1, Nanhu Quan2

  • 1Department of Cardiovascular Center, The First Hospital of Jilin University, Changchun, 130021, China.

Insights

Aging increases cardiovascular disease (CVD) risk. This review explores molecular pathways, cellular processes, and natural products/dietary habits for preventing and treating age-related CVD.

Area of Science:

  • Gerontology
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Cardiovascular diseases (CVDs) are a leading cause of mortality globally, particularly in aging populations.
  • Age-associated CVD mechanisms include oxidative stress, inflammation, and myocardial remodeling.
  • Understanding these processes is crucial for developing effective interventions.

Purpose of the Study:

  • To review key molecular pathways and cellular processes involved in age-related CVD.
  • To explore natural products and dietary habits targeting these mechanisms.
  • To provide insights for reducing the cardiovascular burden in aging individuals.

Main Methods:

  • Literature review of molecular pathways and cellular processes in aging CVD.
  • Analysis of studies on natural products and dietary interventions for cardiovascular health.
  • Examination of evidence from animal models and clinical studies.

Main Results:

  • Identified key molecular and cellular mechanisms contributing to age-related CVD.
  • Highlighted natural products and dietary patterns with potential cardiovascular benefits.
  • Synthesized findings from preclinical and clinical research.

Conclusions:

  • Natural products and specific dietary habits show promise in managing age-related CVD.
  • Further research can elucidate preventive and therapeutic strategies.
  • Recommendations can be developed to mitigate cardiovascular risks in the elderly.

Related Concept Videos

Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.3K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
632
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517